CAS 27851-29-2
:[(3R,4S,5S,6R)-3,4,5,6-tetrabenzyloxitetrahidropiran-2-il]metanol
Fórmula:C34H36O6
InChI:InChI=1/C34H36O6/c35-21-30-31(36-22-26-13-5-1-6-14-26)32(37-23-27-15-7-2-8-16-27)33(38-24-28-17-9-3-10-18-28)34(40-30)39-25-29-19-11-4-12-20-29/h1-20,30-35H,21-25H2/t30?,31-,32+,33+,34-/m1/s1
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Se han encontrado 7 productos.
Benzyl 2,3,4-Tri-O-benzyl-β-D-glucopyranoside
CAS:Fórmula:C34H36O6Pureza:min. 95.0 area%(HPLC)Forma y color:White to Almost white powder to crystalPeso molecular:540.66β-D-Glucopyranoside, phenylmethyl 2,3,4-tris-O-(phenylmethyl)-
CAS:Fórmula:C34H36O6Pureza:95%Forma y color:SolidPeso molecular:540.6460Benzyl 2,3,4-tri-O-benzyl-β-D-glucopyranoside
CAS:Benzyl 2,3,4-tri-O-benzyl-β-D-glucopyranosideFórmula:C34H36O6Pureza:>98%Peso molecular:540.646041,2,3,4-Tetra-O-benzyl-β-D-glucopyranoside
CAS:1,2,3,4-Tetra-O-benzyl-β-D-glucopyranoside is a prodrug that becomes active after acetylation. It is an endogenous compound that has been shown to inhibit the synthesis of myelin and lipid peroxidation in rat brains. This drug has also been found to be effective in the treatment of amyotrophic lateral sclerosis (ALS). 1,2,3,4-Tetra-O-benzyl-β-D-glucopyranoside is unmodified and does not have any side effects on the nervous system. It can be used for the treatment of Parkinson's disease when combined with levodopa.Fórmula:C34H36O6Pureza:Min. 95%Forma y color:White Off-White PowderPeso molecular:540.65 g/molBenzyl 2,3,4-Tri-O-benzyl-β-D-glucopyranoside
CAS:Producto controladoApplications Benzyl 2,3,4-Tri-O-benzyl-β-D-glucopyranoside (cas# 27851-29-2) is a compound useful in organic synthesis.
References Wakao, M., et al.: Bioorg. Med. Chem. Lett., 18, 2499 (2008),Fórmula:C34H36O6Forma y color:NeatPeso molecular:540.65






